
Acumen Pharmaceuticals (ABOS) Stock Forecast & Price Target
Acumen Pharmaceuticals (ABOS) Analyst Ratings
Bulls say
Acumen Pharmaceuticals is viewed favorably because its ACU193-based strategy targets amyloid-beta oligomers, the toxic species thought to drive neuronal injury in Alzheimer’s disease, while avoiding heavier plaque binding that has been linked to higher ARIA risk. The ALTITUDE-AD readout and prior P1 testing support the possibility of a meaningfully cleaner safety profile, with only one symptomatic ARIA-E case reported and preclinical data suggesting 14X–40X higher brain uptake from the TfR-shuttle approach without a clear anemia signal. Fundamentally, the company’s differentiated BBB-crossing platform, on-track mid-2027 IND filing, and the market opportunity implied by a 45% PoS with 2031 market entry and 15% peak penetration underpin the bullish outlook.
Bears say
Acumen Pharmaceuticals is viewed pessimistically because ALTITUDE-AD failed to show that removing amyloid-related pathology translated into cognitive benefit, undermining the core scientific rationale for ACU193 and raising doubts that the company’s shuttle approach can overcome the biology of Alzheimer’s disease. Financially, the company posted an operating loss of $25.8M and a net loss of $25.4M in 3Q26, with $78.6M of cash, cash equivalents, and marketable securities at September 30, 2026, implying a runway only into early 2027 before the program was stopped. With the lead asset derailed, the remaining value appears limited to cash and optionality around licensing or a restart, while regulatory, safety, and execution risks remain elevated.
This aggregate rating is based on analysts' research of Acumen Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Acumen Pharmaceuticals (ABOS) Analyst Forecast & Price Prediction
Start investing in Acumen Pharmaceuticals (ABOS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Acumen Pharmaceuticals (ABOS) Forecast
Acumen Pharmaceuticals (ABOS) Analyst Forecast & Price Prediction
Start investing in Acumen Pharmaceuticals (ABOS)
Order type
Buy in
Order amount
Est. shares
0 shares